A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors

Inclusion Criteria: * Men and women ≥ 18 years old * Must have a pathologically documented, and definitely diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available, or for subjects who refuse standard therapy * Measurable disease by RECIST criteria * Must be able to undergo MRI evaluation * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Competent to sign and date an Institutional Review Board approved informed consent form Exclusion Criteria: * Presence of untreated or symptomatic primary central nervous system tumors or metastases * Presence of leukemia or myelodysplastic syndrome * Subjects with head and neck cancer * Previous hematopoietic stem cell transplant (allogeneic) * Unresolved hematological toxicities \> grade 1 with the exception of grade 2 lymphopenia and non-hematological toxicities \> grade 1, excluding alopecia and grade 2 neuropathy, from prior anti-cancer therapy * Myocardial infarction within 1 year before study day 1, or unstable or uncontrolled disease/condition related to or affecting cardiac function * History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study * Active peripheral vascular disease * History of bleeding diathesis * History of pulmonary hemorrhage or gross hemoptysis within 6 months before study * Known history of adrenal hemorrhage * Known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C * Major surgery within 1 month before study * Prior treatment with any agent targeting the angiopoietin-Tie2 signaling pathway * Concurrent antitumor treatment, except Lupron for subjects with prostate cancer and selective estrogen receptor modulators (SERMS) for subjects with breast cancer, within 4 weeks (6 weeks for nitrosoureas or mitomycin) before study day 1 * Known sensitivity to mammalian-derived products, bacterially-produced proteins, or any of the products to be administered during dosing * Investigational agent within 30 days before study * Pregnant (eg, positive urine test) or breastfeeding * Subjects of childbearing potential, or subject who has a partner of childbearing potential, and is not using highly effective contraceptive precautions